November 2, 2026
Web Announcement 4048

Silver State Scripts Board Made Changes to the Preferred Drug List Effective November 1, 2026

The Silver State Scripts Board (SSSB) met on September 17, 2026, and voted to adopt the following changes to the Nevada Medicaid Preferred Drug List (PDL) effective November 1, 2026.

The complete PDL is posted on the "Preferred Drug List" webpage.

Drug Class/Program	Changes
Vasodilators - Oral	• Macitentan placed as preferred with prior authorization • Ambrisentan moved from non-preferred to preferred with prior authorization • Adcirca removed from PDL due to product discontinuation
Targeted Immunomodulators	• Tofacitinib IR and ER tablets placed as preferred with prior authorization • Tofacitinib solution placed as non-preferred • Xeljanz IR tablet and Xeljanz solution moved from preferred with prior authorization to non-preferred • Idacio removed from the PDL due to product discontinuation • Class name adjusted from "Targeted Immunomodulator" to "Targeted Immunomodulators"
Neuropathic Pain/Fibromyalgia Agents	• Milnacipran placed as non-preferred • Drizalma sprinkle capsule placed as non-preferred • Gabapentin ER (generic for Gralise) placed as non-preferred • Cymbalta removed from the PDL due to product discontinuation
Long-Acting Insulins	• Insulin glargine-YFGN pen moved from non-preferred to preferred, keeping insulin glargine-YFGN vial as non-preferred • Basaglar TempoPen and insulin degludec (generic for Tresiba/Tresiba FlexTouch) removed from PDL due to product discontinuation

Colony Stimulating Factors	• Fulphila moved from non-preferred to preferred with prior authorization • Filkri, Fylnetra, Nypozi, Rolvedon, Ryzneuta, and Stimufend placed as non-preferred
Antiglaucoma Agents	• Phospholine iodide removed from the PDL due to product no longer participating in the Medicaid Drug Rebate Program (MDRP) • Timolol (generic for Timoptic Ocudose) placed as non-preferred • Zolymbus gel placed as non-preferred • Betoptic, Betoptic S, Betagan, Ocupress, Timoptic, Timoptic-XE, Trusopt, and Xelpros removed from the PDL due to product discontinuation
Omega-3 Fatty Acids	• Vascepa and Lovaza removed from the PDL due to these products no longer participating in the Medicaid Drug Rebate Program (MDRP)